Tissue Repair Ltd
AASX:TRP0.08
AUD
0.00
(0.00%)
ISIN
AU0000180887
Return %
Stock
S&P 500
1Y
-72.33
14.39
3Y
-69.82
81.42
5Y
- -
68.62
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Tony Charara
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Tower A, The Zenith Chatswood NSW Australia 2067
- IPO Date
- Nov 16, 2021
- Website
- tissuerepair.com.au
- Similar Companies
- Business
- Tissue Repair Ltd is an Australian clinical-stage biopharmaceutical company specializing in the development of advanced wound healing technologies for chronic wounds and cosmetic procedure aftercare. The company’s core products include TR-987, a proprietary topical drug candidate currently in Phase III clinical trials targeting chronic wounds such as venous leg ulcers; and TR Pro+, a post-procedure cosmeceutical gel designed to accelerate healing and improve skin quality following minimally invasive cosmetic and medical procedures. Tissue Repair’s technology platform, Glucoprime, is based on a unique yeast-derived beta-glucan active pharmaceutical ingredient that stimulates the innate dermal immune system via macrophage activation, promoting tissue regeneration, wound closure, and improved cosmetic outcomes. The company also pursues applications in burns, veterinary products, and new wound care bandages and scaffolds impregnated with its active ingredient. Recent major developments include securing Therapeutic Goods Administration (TGA) approval for TR Pro+ as an Australian listed medicine, significantly expanding its market access and enabling broader promotion and distribution, with the product now adopted in nearly 300 clinics showing consistent monthly sales growth. Tissue Repair is progressing with pivotal Phase III trials of its lead drug candidate TR-987 in Australia and the US, with a planned trial commencement in 2024 subject to FDA approval. The company has undergone strategic leadership activity in 2024 involving key shareholder discussions on company direction and governance, reflecting efforts to optimize its corporate strategy to support ongoing clinical and commercial objectives. Founded in 2005 and headquartered in Chatswood, New South Wales, Tissue Repair operates primarily in Australia and the United States. Its target markets encompass chronic wound care for conditions with long-standing unmet medical needs, and the aesthetic procedure market for enhancing post-procedure healing. The company’s ongoing clinical focus includes leveraging its immunomodulatory drug platform to become a frontline therapy in chronic wound management, an area that has seen limited innovation for over two decades. Tissue Repair’s product portfolio and pipeline emphasize a scientifically robust wound healing approach combining immunology and biopharmaceutical innovation, positioning it as a notable entity in biotech focused on wound care and dermatological repair solutions. This description reflects information available through 2025, including the company’s latest product approvals, clinical trial progress, and strategic developments.